Survival statistics for adrenal gland cancer

Last medical review:

Survival statistics for cancer are very general estimates and must be interpreted very carefully. Because these statistics are based on the experience of groups of people, they cannot be used to predict a particular person's chances of survival.

There are many different ways to measure and report cancer survival statistics. Your doctor can explain these statistics and what they mean to you.

Net survival

Net survival represents the probability (chance) of surviving cancer in the absence of other causes of death. It is used to give an estimate of the percentage of people who will survive cancer.

In Canada, a separate 5-year net survival statistic is not reported for adrenal gland cancer. But it is included in other endocrine cancers, which includes similar cancers that are grouped and reported together. This statistic does not necessarily reflect the actual survival for the individual cancers within the group. The 5-year net survival for all other endocrine cancers is 59%. This means that, on average, people diagnosed with other endocrine cancers are 59% as likely to live at least 5 years after their diagnosis as people in the general population.

Survival by stage and tumour type

Survival varies with each stage and particular type of adrenal gland cancer.

Survival for adrenal gland cancer by stage is reported as 5-year relative survival. Relative survival looks at how likely people with cancer are to survive for at least 5 years after their diagnosis compared to people in the general population who do not have cancer but who share similar characteristics (such as age and sex).

There are no specific Canadian statistics available for the different stages or types of adrenal gland cancer. The following information comes from a variety of sources. It includes statistics from other countries that are likely to have similar outcomes as in Canada.

Adrenocortical carcinoma (ACC) survival

The 5-year relative survival for adrenocortical carcinoma is estimated to be between 38% and 73% depending on the grade and stage of the cancer.

Cancerous pheochromocytoma survival

The 5-year relative survival for cancerous pheochromocytoma is estimated to be between 34% and 60% depending on the grade and stage of the cancer.

Questions about survival

Talk to your doctor about your prognosis. A prognosis depends on many factors, including:

  • your health history
  • the type of cancer
  • the stage
  • the treatments chosen
  • how the cancer responds to treatment

Only a doctor familiar with these factors can put all of this information together with survival statistics to arrive at a prognosis.

Expert review and references

  • Shereen Ezzat, MD, FRCPC, FACP
  • American Cancer Society. Adrenal Cancer. 2018: https://www.cancer.org/.
  • American Society of Clinical Oncology (ASCO) . Cancer.net: Adrenal Gland Tumor . 2022 .
  • American Society of Clinical Oncology (ASCO) . Cancer.net: Pheochromocytoma and Paraganglioma . 2022 .
  • PDQ Adult Treatment Editorial Board. Pheochromocytoma and Paraganglioma Treatment (PDQ®) – Health Professional Version. Bethesda, MD: National Cancer Institute; 2022: https://www.cancer.gov/.
  • Statistics Canada. Table 13-10-0160-01 Age-standardized five-year net survival estimates for primary sites of cancer, by sex, three years combined . https://www.statcan.gc.ca/en/start.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society